LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
+5.39%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$749M
AUM Growth
+$749M
(+33%)
Cap. Flow
+$23.7M
Cap. Flow
% of AUM
3.17%
Top 10 Holdings %
Top 10 Hldgs %
54.66%
Holding
60
New
18
Increased
9
Reduced
11
Closed
12
Top Buys
| 1 |
Jazz Pharmaceuticals
JAZZ
|
$47.8M |
| 2 |
Biogen
BIIB
|
$25.1M |
| 3 |
United Therapeutics
UTHR
|
$24.4M |
| 4 |
Arvinas
ARVN
|
$24.3M |
| 5 |
Neurocrine Biosciences
NBIX
|
$18.9M |
Top Sells
| 1 |
CBIO
Crescent Biopharma, Inc. Common Stock
CBIO
|
$78.2M |
| 2 |
Nuvalent
NUVL
|
$35.5M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$26.1M |
| 4 |
Unicycive Therapeutics
UNCY
|
$22M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$21.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
89bio
ETNB
$1.34B
| – | – |
-2,500,000
| Closed | -$18.2M |
|
52
Geron
GERN
$893M
| – | – |
-8,000,000
| Closed | -$12.7M |
|
53
Larimar Therapeutics
LRMR
$310M
| – | – |
0
| – | – |
|
|
54
Nuvalent
NUVL
$5.52B
| – | – |
-500,000
| Closed | -$35.5M |
|
55
Solid Biosciences
SLDB
$427M
| – | – |
-100,000
| Closed | -$370K |
|
56
Soleno Therapeutics
SLNO
$3.6B
| – | – |
-250,000
| Closed | -$17.9M |
|
|
57
Teva Pharmaceuticals
TEVA
$21.1B
| – | – |
-1,700,000
| Closed | -$26.1M |
|
58
SPDR S&P Biotech ETF
XBI
$5.07B
| – | – |
0
| – | – |
|
|
59
Xenon Pharmaceuticals
XENE
$2.98B
| – | – |
-650,000
| Closed | -$21.8M |
|
|
ARTV
60
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$76.7M
| – | – |
-145,089
| Closed | -$435K |
|